Merck & Company, Inc. (MRK – Q2FY20) – KEYTRUDA expected to bring revenue growth.

in , on October 5, 2020

In oncology, KEYTRUDA sales grew 31% year-over-year, reaching $3.4bn in the quarter. In the U.S., KEYTRUDA demonstrated strong growth across all key tumor types. It received FDA approval for a 6-week dosing regimen across all adult indications, which enabled greater patient access and contributed to growth.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q2FY20 – Results Overview
– 1HFY20 – Results Overview.
– Q2FY20– Segment Performance
– Q2FY20 – R&D Update
– FY20 – Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per share Items and Key ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 63

Release Information

  • Released
    :

    October 5, 2020

  • Last Updated
    :

    October 5, 2020